Sarah Aitken, MBChB, PhD
Cards
Contact Info
About
Copy Link
Titles
Assistant Professor
Biography
Sarah Aitken, MBChB PhD FRCPath, is an Assistant Professor of Pathology and a member of the Center of Molecular and Cellular Oncology (CMCO) at Yale Cancer Center. She is a Pathologist Clinician Scientist, specializing in gastrointestinal and molecular pathology.
Dr Aitken trained in Medicine (MBChB) at the University of Edinburgh, UK, with an intercalated BMedSci in Experimental Pathology and postgraduate MSc in Translational Medicine. She undertook a mixed experimental-computational PhD at the CRUK Cambridge Institute (University of Cambridge, UK), followed by an EMBO Fellowship in bioinformatics at the IRB Barcelona (Spain). She returned to Cambridge to complete her clinical residency in Histopathology (FRCPath) as an NIHR Academic Clinical Fellow and subsequently NIHR Clinical Lecturer. Prior to joining Yale University, Dr Aitken was an independent Group Leader at the University of Cambridge and Consultant Pathologist (Board Certified Attending) at Cambridge University Hospitals NHS Foundation Trust (UK).
Dr Aitken’s lab uses genomic pathology, which combines molecular biology, genomics, and image analysis, to study mechanisms of mutagenesis, the genetic and epigenetic basis of carcinogenesis, and the consequences of genetic diversity on cancer evolution.
Departments & Organizations
- Aitken Lab
- All Institutions
- Center of Molecular and Cellular Oncology
- Genomics, Genetics, and Epigenetics
- Horstmann House Affiliates
- Human Genome Sciences
- Janeway Society
- Molecular Medicine, Pharmacology, and Physiology
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
Education & Training
- Clinical Lecturer & Pathology Resident
- University of Cambridge (2021)
- EMBO Visiting Fellow
- IRB Barcelona (2018)
- PhD
- University of Cambridge , Medical Science (2018)
- Academic Clinical Fellow & Pathology Resident
- Cambridge University Hospitals NHS Foundation Trust (2014)
- MSc
- University of Edinburgh, Translational Medicine (2014)
- MBChB
- University of Edinburgh, Medicine and Surgery (2010)
- BMedSci
- University of Edinburgh, Experimental Pathology (2007)
Advanced Training & Certifications
- Fellow of the Royal College of Pathologists (FRCPath)
- Royal College of Pathologists (2021)
- Certificate of Higher Autopsy Training (CHAT)
- Royal College of Pathologists (2019)
Board Certifications
Histopathology
- Certification Organization
- General Medical Council (UK)
- Original Certification Date
- 2021
Research
Copy Link
Overview
Among the most critical - and yet least understood - stages of cancer formation are the earliest. To address this, our lab seeks to understand the causes and consequences of DNA damage in human health and disease, and how the resultant mutations and genome instability contribute to tumourigenesis.
We recently discovered a phenomenon termed “DNA lesion segregation” (Aitken et al, Nature 2020) which explains how the persistence of DNA lesions through mitosis acts as an engine for genetic diversity and the creation of multiallelic variation in daughter cells. We found persistent DNA lesions in human cancer genomes, which are also ubiquitously present in human cell lines treated with a breadth of common environmental mutagens, including ultraviolet light, tobacco smoke (benzopyrene), and chemotherapeutics (temozolomide). More recently, it was shown that such DNA lesions can also persist in normal tissues for months to years. Understanding the resultant ubiquity of somatic mosaicism across our tissues has wide-reaching implications for normal embryonic development, healthy ageing, chronic disease, and cancer initiation and promotion.
Our multidisciplinary team of computational, experimental, and clinical scientists and collaborators is now applying genomic pathology approaches (combining molecular biology, genomics, and spatial transcriptomics) to model systems and primary human tissues.
Medical Research Interests
ORCID
0000-0002-1897-4140- View Lab Website
Lab Website
Research at a Glance
Publications Timeline
Research Interests
DNA Damage
DNA Repair
Neoplasms
Mutagenesis
Carcinoma
DNA Replication
Publications
Featured Publications
Strand-resolved mutagenicity of DNA damage and repair
Anderson C, Talmane L, Luft J, Connelly J, Nicholson M, Verburg J, Pich O, Campbell S, Giaisi M, Wei P, Sundaram V, Connor F, Ginno P, Sasaki T, Gilbert D, López-Bigas N, Semple C, Odom D, Aitken S, Taylor M. Strand-resolved mutagenicity of DNA damage and repair. Nature 2024, 630: 744-751. PMID: 38867042, PMCID: PMC11186772, DOI: 10.1038/s41586-024-07490-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDNA damageDNA damage-induced mutationsSingle-base resolutionCancer genome evolutionDamage-induced mutationsRepair of DNA damageNucleotide excision repairGenome evolutionMultiple distinct mutationsDNA accessibilityGenomic conditionsReplicative strandProcess genomesDNA base damageTranslesion polymerasesExcision repairDNAMutation patternsMutationsBase damageRepair efficiencyStrandsAlkyl adductsReplicationIdentity fidelityThe artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Pan X, AbdulJabbar K, Coelho-Lima J, Grapa A, Zhang H, Cheung A, Baena J, Karasaki T, Wilson C, Sereno M, Veeriah S, Aitken S, Hackshaw A, Nicholson A, Jamal-Hanjani M, Swanton C, Yuan Y, Le Quesne J, Moore D. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Nature Cancer 2024, 5: 347-363. PMID: 38200244, PMCID: PMC10899116, DOI: 10.1038/s43018-023-00694-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsTitration of RAS alters senescent state and influences tumour initiation
Chan A, Zhu H, Narita M, Cassidy L, Young A, Bermejo-Rodriguez C, Janowska A, Chen H, Gough S, Oshimori N, Zender L, Aitken S, Hoare M, Narita M. Titration of RAS alters senescent state and influences tumour initiation. Nature 2024, 633: 678-685. PMID: 39112713, PMCID: PMC11410659, DOI: 10.1038/s41586-024-07797-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTumor typesOncogenic RAS-induced senescenceInfluence tumor initiationProgenitor-like featuresTumor-initiating phenotypeSingle-cell RNA sequencing analysisModel in vivoHCC subclassesModel in vitroHepatocellular carcinomaTumor suppressor mechanismEarly tumorigenesisTumor initiationEarly-onsetProgenitor featuresInduce tumorsSuppressor mechanismTumorLate-onsetRNA sequencing analysisOncogenic stressRas-induced senescenceIn vivoMolecular signaturesOncogene dosageConvergent somatic mutations in metabolism genes in chronic liver disease
Ng S, Rouhani F, Brunner S, Brzozowska N, Aitken S, Yang M, Abascal F, Moore L, Nikitopoulou E, Chappell L, Leongamornlert D, Ivovic A, Robinson P, Butler T, Sanders M, Williams N, Coorens T, Teague J, Raine K, Butler A, Hooks Y, Wilson B, Birtchnell N, Naylor H, Davies S, Stratton M, Martincorena I, Rahbari R, Frezza C, Hoare M, Campbell P. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 2021, 598: 473-478. PMID: 34646017, DOI: 10.1038/s41586-021-03974-6.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSomatic mutationsConvergent evolutionNon-alcoholic fatty liver diseaseMetabolic genesAlcohol-related liver diseaseFatty liver diseaseFrequent convergent evolutionRegulation of metabolic pathwaysLiver diseaseExcess of mutationsLipid droplet metabolismHepatocellular carcinomaBurden of somatic mutationsStorage triacylglycerolsAcquisition of somatic mutationsNuclear exportIndependent clonesChronic liver diseases to hepatocellular carcinomaIncreased clone sizePositive selectionMaster regulatorsTranscription factorsInsulin signalingChronic liver diseaseMetabolic pathwaysPervasive lesion segregation shapes cancer genome evolution
Aitken S, Anderson C, Connor F, Pich O, Sundaram V, Feig C, Rayner T, Lukk M, Aitken S, Luft J, Kentepozidou E, Arnedo-Pac C, Beentjes S, Davies S, Drews R, Ewing A, Kaiser V, Khamseh A, López-Arribillaga E, Redmond A, Santoyo-Lopez J, Sentís I, Talmane L, Yates A, Semple C, López-Bigas N, Flicek P, Odom D, Taylor M. Pervasive lesion segregation shapes cancer genome evolution. Nature 2020, 583: 265-270. PMID: 32581361, PMCID: PMC7116693, DOI: 10.1038/s41586-020-2435-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChromosome-scale phasingDNA lesionsAcquisition of oncogenic mutationsAlternative allelesGenetic diversityMultiple cell generationsCancer genomesLesion segregationDNA replicationMutagenic DNA lesionsDaughter cellsBase pairsCell divisionCell cycleExogenous mutagensHuman cellsOncogenic selectionOncogenic mutationsMouse liver tumorsDNACell generationDNA base pairsMutationsCellsGenomeSomatic mutations and clonal dynamics in healthy and cirrhotic human liver
Brunner S, Roberts N, Wylie L, Moore L, Aitken S, Davies S, Sanders M, Ellis P, Alder C, Hooks Y, Abascal F, Stratton M, Martincorena I, Hoare M, Campbell P. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 2019, 574: 538-542. PMID: 31645727, PMCID: PMC6837891, DOI: 10.1038/s41586-019-1670-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic liver diseaseHepatocellular carcinomaLiver diseaseCirrhotic liverMutational burdenSomatic mutationsMutational signaturesProgression to chronic liver diseaseSynchronous hepatocellular carcinomaNon-malignant hepatocytesExcessive alcohol intakeComplexity of hepatocellular carcinomaBands of fibrosisNon-alcoholic fatty liver diseaseStructural variantsFatty liver diseaseGenome of hepatocellular carcinomaClinical spectrumAlcohol intakeLiver failureViral hepatitisClonal expansionMalignant transformationHealth to diseaseRegenerative nodulesCTCF maintains regulatory homeostasis of cancer pathways
Aitken S, Ibarra-Soria X, Kentepozidou E, Flicek P, Feig C, Marioni J, Odom D. CTCF maintains regulatory homeostasis of cancer pathways. Genome Biology 2018, 19: 106. PMID: 30086769, PMCID: PMC6081938, DOI: 10.1186/s13059-018-1484-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsBreast NeoplasmsCCCTC-Binding FactorCell LineChromatinDNA, NeoplasmEnhancer Elements, GeneticFemaleFibroblastsGene Expression Regulation, NeoplasticGenomeHemizygoteHomeostasisHumansLiver Neoplasms, ExperimentalMiceMice, Inbred C57BLMice, TransgenicProtein BindingSignal TransductionUterine NeoplasmsConceptsTranscriptional regulationIntra-TAD interactionsSteady-state gene expressionCancer-related pathwaysMammalian genomesCTCF occupancyGenome functionChromatin loopsEvolutionary conservationChromatin structureGenomic dysregulationRegulatory domainHemizygous cellsEpigenomic profilingCTCFCTCF expressionMammalian cellsExpressed genesAffinity binding eventsTranscriptional alterationsGene expressionMouse lineagesCancer pathwaysMouse model systemHuman cancers
2025
Under the microscope: DNA damage tracked through cell generations
Reilly E, Aitken S. Under the microscope: DNA damage tracked through cell generations. Nature 2025, 642: 576-577. PMID: 40399519, DOI: 10.1038/d41586-025-01446-9.Peer-Reviewed Original ResearchAltmetricDNA lesions piece together impossible trees
Arnedo-Pac C, Aitken S. DNA lesions piece together impossible trees. Trends In Genetics 2025, 41: 456-458. PMID: 40180876, DOI: 10.1016/j.tig.2025.03.002.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and Concepts
2024
Novel immunotherapeutics against LGR5 to target multiple cancer types
Chen H, Mueller N, Stott K, Kapeni C, Rivers E, Sauer C, Beke F, Walsh S, Ashman N, O’Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken S, Hoare M, Mair R, Serrao E, Brenton J, Garcia-Gimenez A, Richardson S, Huntly B, Spring D, Skjoedt M, Skjødt K, de la Roche M, de la Roche M. Novel immunotherapeutics against LGR5 to target multiple cancer types. EMBO Molecular Medicine 2024, 16: 2233-2261. PMID: 39169164, PMCID: PMC11393416, DOI: 10.1038/s44321-024-00121-2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHepatocellular carcinomaColorectal cancerTarget multiple cancer typesBispecific T-cell engagerCell killing in vitroChimeric antigen receptorT-cell engagersCancer cells in vitroPre-B-ALLAnti-tumor efficacyCancer cell killing in vitroKilling in vitroCells in vitroAntibody-drug conjugatesMultiple cancer typesLGR5 overexpressionTumor burdenAntigen receptorMurine modelNovel immunotherapeuticsCancer modelsTumor cellsEffective modalityEffective tumorLgr5
Academic Achievements & Community Involvement
Copy Link
Honors
honor Wyllie Lecture and Medal
01/21/2026International AwardPathological Society of Great Britain & IrelandDetailsUnited Kingdomhonor CRUK Clinician Scientist Fellowship
09/01/2023International AwardCancer Research UKDetailsUnited Kingdomhonor Sir Nicholas Wright Lecture and Medal
01/27/2021International AwardPathological Society of Great Britain & IrelandDetailsUnited Kingdomhonor Gold Research Medal
11/21/2019International AwardRoyal College of Pathologists, UKDetailsUnited Kingdomhonor Trainee Research Award
12/06/2018International AwardPathological Society of Great Britain & IrelandDetailsUnited Kingdom
Get In Touch
Copy Link